USANA Health Sciences, Inc. (NYSE:USNA) Forecasted to Post Q2 2024 Earnings of $0.68 Per Share

USANA Health Sciences, Inc. (NYSE:USNA) – Equities researchers at DA Davidson issued their Q2 2024 EPS estimates for USANA Health Sciences in a research report issued on Tuesday, May 7th. DA Davidson analyst L. Weiser anticipates that the company will post earnings per share of $0.68 for the quarter. DA Davidson has a “Neutral” rating and a $46.00 price objective on the stock. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.75 per share.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.52 by $0.35. USANA Health Sciences had a net margin of 6.88% and a return on equity of 12.80%. The firm had revenue of $221.08 million during the quarter, compared to the consensus estimate of $206.70 million.

Separately, StockNews.com upgraded USANA Health Sciences from a “buy” rating to a “strong-buy” rating in a report on Friday, January 12th.

USANA Health Sciences Stock Up 0.3 %

USNA opened at $44.74 on Wednesday. USANA Health Sciences has a 52 week low of $41.45 and a 52 week high of $69.60. The company has a market capitalization of $858.91 million, a P/E ratio of 13.94, a PEG ratio of 1.38 and a beta of 0.94. The stock’s fifty day moving average is $46.48 and its two-hundred day moving average is $48.07.

Institutional Investors Weigh In On USANA Health Sciences

Institutional investors have recently added to or reduced their stakes in the business. Quest Partners LLC purchased a new position in shares of USANA Health Sciences in the 4th quarter valued at approximately $66,000. CWM LLC raised its holdings in shares of USANA Health Sciences by 49.6% in the fourth quarter. CWM LLC now owns 1,267 shares of the company’s stock worth $68,000 after buying an additional 420 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of USANA Health Sciences by 60.6% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,376 shares of the company’s stock worth $198,000 after buying an additional 1,274 shares during the period. Trexquant Investment LP purchased a new stake in shares of USANA Health Sciences during the fourth quarter valued at $266,000. Finally, Teacher Retirement System of Texas acquired a new position in shares of USANA Health Sciences in the 3rd quarter valued at $297,000. Institutional investors and hedge funds own 54.25% of the company’s stock.

Insiders Place Their Bets

In other news, CFO G Doug Iiekking sold 5,198 shares of the business’s stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $44.76, for a total value of $232,662.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Robert A. Sinnott sold 3,945 shares of the company’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $46.55, for a total transaction of $183,639.75. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO G Doug Iiekking sold 5,198 shares of the firm’s stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $44.76, for a total value of $232,662.48. The disclosure for this sale can be found here. Insiders sold a total of 34,286 shares of company stock worth $1,634,010 over the last 90 days. Company insiders own 0.33% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.